Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19330910 | 0.88 | TAAR1 (0.38) | HDAC3HDAC1HDAC7HDAC2HDAC8 | |
| SCHEMBL991567 | 0.84 | CYP2A6 (0.42) | TAAR1 | |
| Hydrochloric Acid SCHEMBL5060581 | 0.82 | KDM1A (0.40) | — | |
| SCHEMBL255382 | 0.80 | AKT2 (0.44) | — | |
| SCHEMBL9966307 | 0.80 | AKT1 (0.41) | — | |
| SCHEMBL26504589 | 0.79 | OPRM1 (0.32) | — | |
| SCHEMBL1240436 | 0.79 | MAOB (0.41) | HDAC3HDAC1HDAC2 | |
| SCHEMBL14315747 | 0.79 | ESR2 (0.43) | — | |
| SCHEMBL26504450 | 0.79 | LMNA (0.40) | LMNA | |
| SCHEMBL8155581 | 0.79 | ALDH1A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| CN-113072546-B | Five-membered heteroaromatic derivative and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2024187126-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | AQUINNAH PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2023-09-14 | — | — | US | disclosed |
| US-11691977-B2 | Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11691977-B2 | Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20230000871-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-01-05 | — | — | US | disclosed |
| EP-4055015-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2022-09-14 | — | — | EP | disclosed |
| CN-115038700-A | Gem disubstituted heterocyclic compounds and their use as IDH inhibitors | 内尔维亚诺医疗科学公司 | 2022-09-09 | — | — | CN | disclosed |
| US-10479794-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-11-19 | — | — | US | disclosed |
| US-10023575-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10023575-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180134720-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2018-05-17 | — | — | US | disclosed |
| US-20180134720-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INT (DE) | 2018-05-17 | — | — | US | disclosed |
| WO-2017064082-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-04-20 | — | — | WO | disclosed |
| EP-3156405-A1 | SPIROCYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE | Boehringer Ingelheim International GmbH (DE) | 2017-04-19 | — | — | EP | disclosed |
| US-20170101411-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101411-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-04-13 | — | — | US | disclosed |
| WO-2012082817-A1 | BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479794-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | CNP, PDE5A, PDE3A | HDAC3 999/4885HDAC1 1260/4885HDAC7 1657/4885 |
| US-20180134720-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | CNP, PDE5A, PDE3A | HDAC3 999/4885HDAC1 1260/4885HDAC7 1657/4885 |
| US-20230286993-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | CNP, PDE3A, PDE5A | HDAC3 644/4885HDAC1 930/4885HDAC7 1878/4885 |
| US-20170101411-A1 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE | CNP, PDE5A, PDE3A | HDAC3 999/4885HDAC1 1260/4885HDAC7 1657/4885 |
| US-20230000871-A1 | GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS | IDH1, IDH2, IDH3A | HDAC3 225/4885HDAC1 129/4885HDAC7 998/4885 |
| US-11691977-B2 | Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide | CNP, PDE5A, PDE3A | HDAC3 999/4885HDAC1 1260/4885HDAC7 1657/4885 |
| US-10023575-B2 | Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide | CNP, PDE5A, PDE3A | HDAC3 999/4885HDAC1 1260/4885HDAC7 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.